BioLife Solutions Reports Strong Q4 & FY25 Results, Guides for 2026 GAAP Profitability
Summary
BioLife Solutions announced robust fourth quarter and full year 2025 financial results, exceeding revenue expectations and projecting a return to full-year GAAP profitability in 2026.
Key Events
-
Strong Q4 & FY25 Revenue Growth
Reported Q4 2025 revenue of $24.8 million, an increase of 20% year-over-year, and full year 2025 revenue of $96.2 million, up 29% year-over-year.
-
Return to Q4 GAAP Profitability
Achieved GAAP net income of $2.1 million, or $0.04 per share, for Q4 2025, reversing a net loss of $1.2 million in Q4 2024.
-
Positive 2026 Financial Guidance
Introduced 2026 revenue guidance of $112.5 million to $115.0 million, representing 17% to 20% growth, and expects full-year GAAP profitability.
-
Adjusted EBITDA Expansion
Reported Q4 2025 Adjusted EBITDA of $6.9 million (28% of revenue) and FY 2025 Adjusted EBITDA of $25.0 million (26% of revenue), with continued expansion expected in 2026.
Analysis
This filing provides the full financial results for Q4 and full year 2025, building on the preliminary revenue announced in January. The company reported significant revenue growth and a positive shift to GAAP net income in Q4 2025. Most notably, BioLife Solutions introduced 2026 guidance that includes an expectation of full-year GAAP profitability, a key milestone following its strategic divestitures to become a focused cell processing company. This outlook, coupled with strong adjusted EBITDA expansion, signals improved operational efficiency and a positive trajectory for the company's financial health.
At the time of this filing, BLFS was trading at $23.08 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $19.10 to $29.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.